ACM
KROS icon

ADAR1 Capital Management’s Keros Therapeutics KROS Stock Holding History

ADAR1 Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.64M Buy
246,818
+149,500
+154% +$1.67M 0.12% 131
2026
Q1 		$1.07M Buy
97,318
+78,467
+416% +$1.21M 0.06% 151
2025
Q4 		$384K Sell
18,851
-5,370,413
-100% -$94.2M 0.03% 200
2025
Q3 		$85.3M Hold
5,389,264
– – 8.01% 2
2025
Q2 		$71.9M Buy
5,389,264
+3,902,803
+263% +$52.7M 11.03% 1
2025
Q1 		$15.1M Buy
1,486,461
+1,463,215
+6,294% +$17M 2.81% 7
2024
Q4 		$368K Sell
23,246
-421,822
-95% -$21.9M 0.07% 127
2024
Q3 		$25.8M Sell
445,068
-103,848
-19% -$5.13M 4.2% 8
2024
Q2 		$25.1M Buy
548,916
+210,673
+62% +$11.3M 4.74% 7
2024
Q1 		$22.4M Sell
338,243
-350,073
-51% -$20.8M 5.08% 8
2023
Q4 		$27.4M Buy
+688,316
New +$21.6M 9.78% 3

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

ADAR1 Capital Management's KROS Position: Q2 2026 in Review

ADAR1 Capital Management increased its Keros Therapeutics (KROS) stake by 154% in Q2 2026, buying an estimated $1.67M and bringing the position to 246,818 shares worth $2.64M. The position accounts for 0.12% of the portfolio, ranked #131.

ADAR1 Capital Management first reported a position in KROS in Q4 2023 and has held it in 11 quarters since. The position peaked at $85.3M in Q3 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • ADAR1 Capital Management held 246,818 shares of Keros Therapeutics worth $2.64M as of Q2 2026.
  • ADAR1 Capital Management bought 149,500 Keros Therapeutics shares in Q2 2026, an estimated $1.67M.
  • Keros Therapeutics made up 0.12% of ADAR1 Capital Management's portfolio in Q2 2026, its #131 holding.
  • ADAR1 Capital Management first reported a position in Keros Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • ADAR1 Capital Management's Keros Therapeutics position peaked at $85.3M in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.